Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme

British Journal of Ophthalmology

Volumn 97, Issue 9, 2013, Pages 1161-1167

  Holz, Frank G ^a   Bandello, Francesco ^b   Gillies, Mark ^c   Mitchell, Paul ^c   Osborne, Aaron ^d   Sheidow, Tom ^e   Souied, Eric ^f   Figueroa, Marta S ^g   Brand, Christopher ^h   Koh, Adrian ⁱ   Schmidt Erfurth, Ursula ^j   Sharma, N ^k   Winyard, Steve ^l  

^a UNIVERSITY OF BONN   (Germany)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Ivey Eye Institute   (Canada)

^f CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁱ Camden Medical Centre   (Singapore)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k AMD Alliance International   (United States)

^l Royal National Institute of Blind People   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; BELGIUM; BRAIN HEMORRHAGE; BRAIN INFARCTION; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EUROPE; EYE INFLAMMATION; FEMALE; FOLLOW UP; GERMANY; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETINA BLOOD FLOW; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT EPITHELIOPATHY; RETINA TEAR; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SWEDEN; VITREOUS HEMORRHAGE;

DEGENERATION; MACULA; TREATMENT MEDICAL;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84882252281     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303232     Document Type: Article

References (29)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
2. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
4. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-602.
5. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-9.
6. Mitchell P, Bandello F, Schmidt-Erfurth UM, et al. The RESTORE Study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
7. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.
8. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
9. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
10. Dreyer N. Designing and assessing registries to evaluate the safety of medical products. Monit Assoc Clin Trial Prof 2007;21:47-50.
11. Dreyer NA, Garner S. Registries for robust evidence. JAMA 2009;302:790-1.
12. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50.
13. Finger RP, Wiedemann P, Blumhagen F, et al. Treatment patterns, visual acuity and quality of life outcomes in the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmologica Published Online First: 22 Nov 2012. doi:10.1111/j.1755-3768.2012.02493.x
14. Finger RP, Holz FG. Access to healthcare services for elderly patients with neovascular age-related macular degeneration. Ophthalmologe 2012;109:474-8.
15. Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol 2011;2011:405724.
16. Rakic J-M, Leys A, Brié H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2012 (In press).
17. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9.
18. Gower EW, Cassard S, Chu L, et al. Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52(ARVO 2011). E-abstract 6644.
19. Martin DF, Maguire MG, Fine SL, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
20. Martin DF, Maguire MG, et al.; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
21. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
22. Carneiro AM, Barthelmes D, Falcao MS, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011;225:211-21.
23. Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215-18.
24. Barros-Pereira R, Costa R, Falcao M, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab or ranibizumab in the treatment of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:2319.
25. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
26. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148:70-8.
27. Stangos AN, Gandhi JS, Nair-Sahni J, et al. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150:666-73.
28. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82.
29. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-6.